Literature DB >> 27272500

Using the cognitive assessment interview to screen cognitive impairment in psychosis.

Ana M Sánchez-Torres1,2,3, María Rosa Elosúa3, Ruth Lorente-Omeñaca1,2, Lucía Moreno-Izco1,2, Victor Peralta1,2, Joseph Ventura4, Manuel J Cuesta5,6.   

Abstract

Cognitive impairment in psychosis is closely related to functional outcome, so research into psychotic disorders is focusing most effort on treatments for improving cognition. New treatments must show not only an improvement on neuropsychological tests but also in co-primary measures of cognition. The cognitive assessment interview (CAI) is an interview-based measure of cognition which assesses the impact of cognitive deficits in patients' daily lives. Information obtained from patients and their relatives is integrated into a rater composite score. This study examines the validity of the CAI (adapted to Spanish, CAI-Sp) as a screening instrument for cognitive impairment, compared to an objective test of cognitive functioning. The psychometric properties of the CAI-Sp and its association with clinical dimensions are also explored. Eighty-one patients with a psychotic disorder and 38 healthy controls were assessed using the CAI-Sp and the screen for cognitive impairment in psychiatry (SCIP-S). Patients also underwent a clinical assessment. Poorer cognitive functioning as assessed with the CAI-Sp was associated to illness severity, specifically positive, negative and disorganised syndromes. Binary logistic regression showed that the CAI-Sp was able to detect cognitive impairment in patients, when considering CAI-Sp patient and informant information and CAI-Sp rater scores. The CAI-Sp was found to be a valid and reliable scale to assess cognitive functioning in the context of its impact on daily living. Given its ease and speed of application, the CAI-Sp could prove useful in clinical practice, though not a substitute of objective cognitive testing.

Entities:  

Keywords:  Cognition; Cognitive assessment interview; Functional outcome; Psychosis; Schizophrenia; Symptoms

Mesh:

Year:  2016        PMID: 27272500     DOI: 10.1007/s00406-016-0700-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  33 in total

1.  Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Bibiana Cabrera; Miquel Bioque; Jessica Merchán-Naranjo; Iluminada Corripio; Ana González-Pinto; Antonio Lobo; Igor Bombín; Elena de la Serna; Julio Sanjuan; Mara Parellada; Jerónimo Saiz-Ruiz; Miquel Bernardo
Journal:  Schizophr Res       Date:  2015-03-26       Impact factor: 4.939

2.  The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.

Authors:  Joseph Ventura; Steven P Reise; Richard S E Keefe; Lyle E Baade; James M Gold; Michael F Green; Robert S Kern; Raquelle Mesholam-Gately; Keith H Nuechterlein; Larry J Seidman; Robert M Bilder
Journal:  Schizophr Res       Date:  2010-06-12       Impact factor: 4.939

3.  Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.

Authors:  Steven P Reise; Joseph Ventura; Richard S E Keefe; Lyle E Baade; James M Gold; Michael F Green; Robert S Kern; Raquelle Mesholam-Gately; Keith H Nuechterlein; Larry J Seidman; Robert Bilder
Journal:  Psychol Assess       Date:  2011-03

4.  The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.

Authors:  Joseph Ventura; Steven P Reise; Richard S E Keefe; Irene M Hurford; Rachel C Wood; Robert M Bilder
Journal:  Schizophr Bull       Date:  2012-02-10       Impact factor: 9.306

5.  Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.

Authors:  Rafael Tabarés-Seisdedos; Vicente Balanzá-Martínez; José Sánchez-Moreno; Anabel Martinez-Aran; José Salazar-Fraile; Gabriel Selva-Vera; Cristina Rubio; Ignacio Mata; Manuel Gómez-Beneyto; Eduard Vieta
Journal:  J Affect Disord       Date:  2008-03-04       Impact factor: 4.839

6.  A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia.

Authors:  S Kristian Hill; James L Reilly; Margret S H Harris; Cherise Rosen; Robert W Marvin; Ovidio Deleon; John A Sweeney
Journal:  Schizophr Res       Date:  2009-05-17       Impact factor: 4.939

7.  Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools.

Authors:  Johan Høy Jensen; Mette Marie Støttrup; Emilie Nayberg; Ulla Knorr; Henrik Ullum; Scot E Purdon; Lars V Kessing; Kamilla W Miskowiak
Journal:  J Affect Disord       Date:  2015-08-01       Impact factor: 4.839

8.  Clinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition.

Authors:  Joseph Ventura; Angel Cienfuegos; Oren Boxer; Robert Bilder
Journal:  Schizophr Res       Date:  2007-09-27       Impact factor: 4.939

9.  Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S).

Authors:  Emilio Rojo; Oscar Pino; Georgina Guilera; Juana Gómez-Benito; Scot E Purdon; Benedicto Crespo-Facorro; Manuel J Cuesta; Manuel Franco; Anabel Martínez-Arán; Nuria Segarra; Rafael Tabarés-Seisdedos; Eduard Vieta; Miguel Bernardo; Francisco Mesa; Javier Rejas
Journal:  Schizophr Res       Date:  2009-09-09       Impact factor: 4.939

10.  Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools.

Authors:  Caroline Vintergaard Ott; Anne Juul Bjertrup; Johan Høy Jensen; Henrik Ullum; René Sjælland; Scot E Purdon; Eduard Vieta; Lars V Kessing; Kamilla W Miskowiak
Journal:  J Affect Disord       Date:  2015-11-10       Impact factor: 4.839

View more
  5 in total

1.  Proteomic analysis of plasma from rheumatoid arthritis patients with mild cognitive impairment.

Authors:  Li Yang; Qing-Hua Zou; Yan Zhang; Yin Shi; Chun-Rong Hu; Cai-Xia Hui; Xiao-Fei Liu; Yong-Fei Fang
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

2.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

3.  Assessment of cognitive impairment in psychosis spectrum disorders through self-reported and interview-based measures.

Authors:  Ana M Sánchez-Torres; Lucía Moreno-Izco; Gustavo J Gil-Berrozpe; Ruth Lorente-Omeñaca; María Zandio; Amalia Zarzuela; Victor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-01       Impact factor: 5.760

4.  Altered resting-state functional connectivity of the cerebellum in schizophrenia.

Authors:  Chuanjun Zhuo; Chunli Wang; Lina Wang; Xinyu Guo; Qingying Xu; Yanyan Liu; Jiajia Zhu
Journal:  Brain Imaging Behav       Date:  2018-04       Impact factor: 3.978

5.  An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI).

Authors:  Tehila Eilam-Stock; Pamela Best; Kathleen Sherman; Michael T Shaw; Joseph Ventura; Lauren B Krupp; Leigh E Charvet
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.